62 related articles for article (PubMed ID: 168907)
1. [Mechanisms of platelet aggregation inhibition caused by sulfonylurea compounds. 4. Discussion, summary, and literature].
Losert VW; Scholz C; Hoder A
Arzneimittelforschung; 1975 Apr; 25(4):547-60. PubMed ID: 168907
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of thrombocyte aggregation inhibition caused by sulfonylurea compounds. 3. Significance of prostaglandins and cAMP for aggregation inhibiting effect and other effects of sulfonylurea compounds].
Scholz VC; Hoder A; Losert W
Arzneimittelforschung; 1975 Mar; 25(3):347-61. PubMed ID: 239727
[No Abstract] [Full Text] [Related]
3. [Experimental studies on mechanism of inhibition of thrombocyte aggregation caused by sulfonyl ureas. 1. Problems and methods].
Scholz Ch; Losert W; Hoder A
Arzneimittelforschung; 1975 Jan; 25(1):38-46. PubMed ID: 167791
[No Abstract] [Full Text] [Related]
4. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
5. [Experimental studies on the mechanism of thrombocyte aggregation inhibition caused by sulfonylurea compounds. 2. Modification of blood sugar and thrombocyte aggregation by oral antidiabetics].
Losert W; Hoder A; Scholz C
Arzneimittelforschung; 1975 Feb; 25(2):170-9. PubMed ID: 804311
[No Abstract] [Full Text] [Related]
6. [Cyclic adenosine monophosphate, prostaglandin E and aggregation of blood platelets in man].
Ardelt W
Fortschr Med; 1977 Feb; 95(6):366-70. PubMed ID: 190100
[TBL] [Abstract][Full Text] [Related]
7. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
[TBL] [Abstract][Full Text] [Related]
8. Antiaggregatory activity of hypoglycaemic sulphonylureas.
Siluk D; Kaliszan R; Haber P; Petrusewicz J; Brzozowski Z; Sut G
Diabetologia; 2002 Jul; 45(7):1034-7. PubMed ID: 12136403
[TBL] [Abstract][Full Text] [Related]
9. Effects of prostaglandins, derivatives of cyclic 3':5'-AMP, theophylline, cholinergic agents and colchicine on clot retraction in dilute platelet-rich plasma and gel-separated platelet test systems.
Moake JL; Cimo PL; Widmer K; Peterson DM; Gum JR
Thromb Haemost; 1977 Aug; 38(2):420-8. PubMed ID: 202038
[TBL] [Abstract][Full Text] [Related]
10. Effect of heparin and dihydroergotamine on platelet adenosine-3',5'-cyclic monophosphate.
Zahavi M; Welzel D; Wolf H; Honey A; Kakkar VV
Arzneimittelforschung; 1987 Jun; 37(6):669-74. PubMed ID: 2822055
[TBL] [Abstract][Full Text] [Related]
11. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
12. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
Ashida SI; Abiko Y
Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
14. Modulation of platelet cyclic nucleotide content by PGE1 and the prostaglandin endoperoxide PGG2.
Miller OV; Gorman RR
J Cyclic Nucleotide Res; 1976; 2(2):79-87. PubMed ID: 177467
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ADP-induced responses in human platelets by agents elevating the cyclic AMP level: comparison of aggregation and shape change.
Steen VM; Holmsen H
Thromb Haemost; 1984 Dec; 52(3):333-5. PubMed ID: 6099615
[TBL] [Abstract][Full Text] [Related]
16. Interaction of prostaglandins E1 and E2 in regulation of cyclic-AMP and aggregation in human platelets: evidence for a common prostaglandin receptor.
McDonald JW; Stuart RK
J Lab Clin Med; 1974 Jul; 84(1):111-21. PubMed ID: 4365532
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives.
Harris DN; Asaad MM; Phillips MB; Goldenberg HJ; Antonaccio MJ
J Cyclic Nucleotide Res; 1979; 5(2):125-34. PubMed ID: 221552
[TBL] [Abstract][Full Text] [Related]
18. Evidence that adenosine diphosphate can activate adenylate cyclase via conversion to adenosine in platelet-rich plasma containing magnesium.
Glenn JR; Heptinstall S
Thromb Haemost; 1998 Aug; 80(2):321-5. PubMed ID: 9716160
[TBL] [Abstract][Full Text] [Related]
19. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
20. Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro.
Nunn B
Thromb Haemost; 1981 Feb; 45(1):1-5. PubMed ID: 7245119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
